|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 2
Zeitschriftenartikel
Strube, Wolfgang; Aksar, Aslihan; Bauer, Ingrid; Barbosa, Susana; Benros, Michael; Blankenstein, Christiane; Campana, Mattia; Davidovic, Laetitia; Glaichenhaus, Nicolas; Falkai, Peter; Gorlitz, Thomas; Hansbauer, Maximilian; Heilig, Daniel; Khalfallah, Olfa; Leboyer, Marion; Martinuzzi, Emanuela; Mayer, Susanne; Moussiopoulou, Joanna; Papazova, Irina; Peric, Natasa; Wagner, Elias; Schneider-Axmann, Thomas; Simon, Judit und Hasan, Alkomiet
(2022):
Effects of add-on Celecoxib treatment on patients with schizophrenia spectrum disorders and inflammatory cytokine profile trial (TargetFlame): study design and methodology of a multicentre randomized, placebo-controlled trial.
In: Journal of Neural Transmission, Bd. 130, Nr. 8: S. 1039-1048
Hasan, Alkomiet; Roeh, Astrid; Leucht, Stefan; Langguth, Berthold; Hansbauer, Maximilian; Oviedo-Salcedo, Tatiana; Kirchner, Sophie K.; Papazova, Irina; Loehrs, Lisa; Wagner, Elias; Maurus, Isabel; Strube, Wolfgang; Rossner, Moritz J.; Wehr, Michael C.; Bauer, Ingrid; Heres, Stephan; Leucht, Claudia; Kreuzer, Peter M.; Zimmermann, Stephanie; Schneider-Axmann, Thomas; Goerlitz, Thomas; Karch, Susanne; Egert-Schwender, Silvia; Schossow, Beate; Rothe, Philipp und Falkai, Peter
(2020):
Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial.
In: Contemporary Clinical Trials Communications, Bd. 17, 100537